Loading...

AmpliPhi Biosciences

DB:TG1M
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TG1M
DB
$10M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • AmpliPhi Biosciences has significant price volatility in the past 3 months.
TG1M Share Price and Events
7 Day Returns
-10.3%
DB:TG1M
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-72.4%
DB:TG1M
-10.6%
DE Biotechs
-6.2%
DE Market
TG1M Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AmpliPhi Biosciences (TG1M) -10.3% -3.6% 23.4% -72.4% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • TG1M underperformed the Biotechs industry which returned -10.6% over the past year.
  • TG1M underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
TG1M
Industry
5yr Volatility vs Market
Related Companies

Value

 Is AmpliPhi Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AmpliPhi Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €0.243.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AmpliPhi Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AmpliPhi Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TG1M PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.64
AMEX:APHB Share Price ** AMEX (2019-04-23) in USD $0.31
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AmpliPhi Biosciences.

DB:TG1M PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:APHB Share Price ÷ EPS (both in USD)

= 0.31 ÷ -0.64

-0.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AmpliPhi Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • AmpliPhi Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does AmpliPhi Biosciences's expected growth come at a high price?
Raw Data
DB:TG1M PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-11.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AmpliPhi Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AmpliPhi Biosciences's assets?
Raw Data
DB:TG1M PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.26
AMEX:APHB Share Price * AMEX (2019-04-23) in USD $0.31
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:TG1M PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:APHB Share Price ÷ Book Value per Share (both in USD)

= 0.31 ÷ 0.26

1.17x

* Primary Listing of AmpliPhi Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AmpliPhi Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess AmpliPhi Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AmpliPhi Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AmpliPhi Biosciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-11.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AmpliPhi Biosciences expected to grow at an attractive rate?
  • Unable to compare AmpliPhi Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare AmpliPhi Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • AmpliPhi Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TG1M Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TG1M Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -11.7%
DB:TG1M Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 99.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TG1M Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TG1M Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 4 -18 1
2020-12-31 0 -15 2
2019-12-31 0 -15 2
DB:TG1M Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -9 -12
2018-09-30 0 -9 -10
2018-06-30 0 -9 -9
2018-03-31 0 -9 -13
2017-12-31 0 -9 -13
2017-09-30 0 -8 -20
2017-06-30 0 -11 -23
2017-03-31 0 -11 -23
2016-12-31 0 -11 -24
2016-09-30 0 -11 -18
2016-06-30 0 -11 -16
2016-03-31 0 -11 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AmpliPhi Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • AmpliPhi Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TG1M Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from AmpliPhi Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TG1M Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.37 -0.37 -0.37 1.00
2020-12-31 -0.31 -0.29 -0.33 2.00
2019-12-31 -0.45 -0.45 -0.45 1.00
DB:TG1M Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.64
2018-09-30 -0.73
2018-06-30 -0.77
2018-03-31 -1.37
2017-12-31 -2.01
2017-09-30 -4.61
2017-06-30 -9.60
2017-03-31 -18.06
2016-12-31 -24.67
2016-09-30 -22.68
2016-06-30 -24.43
2016-03-31 -4.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AmpliPhi Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AmpliPhi Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AmpliPhi Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AmpliPhi Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AmpliPhi Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AmpliPhi Biosciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare AmpliPhi Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AmpliPhi Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AmpliPhi Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AmpliPhi Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TG1M Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -12.11 5.70
2018-09-30 0.02 -10.14 5.52
2018-06-30 0.06 -9.32 5.86
2018-03-31 0.09 -12.73 7.28
2017-12-31 0.12 -12.84 7.09
2017-09-30 0.12 -19.99 7.83
2017-06-30 0.11 -22.80 8.00
2017-03-31 0.18 -22.69 7.67
2016-12-31 0.26 -24.28 8.41
2016-09-30 0.37 -17.96 9.03
2016-06-30 0.48 -16.09 8.79
2016-03-31 0.48 -2.52 7.96
2015-12-31 0.48 -10.79 6.71
2015-09-30 0.45 -14.68 6.12
2015-06-30 0.41 7.93 6.28
2015-03-31 0.41 14.26 6.62
2014-12-31 0.41 15.76 6.85
2014-09-30 0.06 23.05 6.51
2014-06-30 -0.05 -46.88 6.03
2014-03-31 0.16 -75.18 6.91
2013-12-31 0.08 -65.20 6.00
2013-09-30 0.35 -66.88 5.69
2012-12-31 0.66 -4.26 3.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AmpliPhi Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AmpliPhi Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AmpliPhi Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AmpliPhi Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AmpliPhi Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AmpliPhi Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AmpliPhi Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AmpliPhi Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AmpliPhi Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AmpliPhi Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • AmpliPhi Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AmpliPhi Biosciences Company Filings, last reported 3 months ago.

DB:TG1M Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 8.47 0.00 8.16
2018-09-30 6.85 0.00 4.50
2018-06-30 8.34 0.00 5.80
2018-03-31 11.29 0.00 8.21
2017-12-31 7.73 0.00 5.13
2017-09-30 9.76 0.31 7.73
2017-06-30 9.86 0.61 8.96
2017-03-31 6.65 0.60 2.20
2016-12-31 9.72 0.80 5.71
2016-09-30 18.23 0.00 3.97
2016-06-30 21.48 0.00 7.14
2016-03-31 22.60 0.00 6.17
2015-12-31 26.10 0.00 9.37
2015-09-30 28.73 0.00 11.74
2015-06-30 27.14 0.00 14.35
2015-03-31 18.68 0.00 16.63
2014-12-31 17.75 0.00 6.58
2014-09-30 20.07 0.00 9.79
2014-06-30 16.82 0.00 12.55
2014-03-31 13.33 0.00 16.44
2013-12-31 18.87 0.00 20.36
2013-09-30 6.41 0.00 4.86
2012-12-31 12.94 3.65 0.86
  • AmpliPhi Biosciences has no debt.
  • AmpliPhi Biosciences had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AmpliPhi Biosciences has less than a year of cash runway based on current free cash flow.
  • AmpliPhi Biosciences has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.2% each year.
X
Financial health checks
We assess AmpliPhi Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AmpliPhi Biosciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AmpliPhi Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AmpliPhi Biosciences dividends.
If you bought €2,000 of AmpliPhi Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AmpliPhi Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AmpliPhi Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TG1M Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TG1M Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AmpliPhi Biosciences has not reported any payouts.
  • Unable to verify if AmpliPhi Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AmpliPhi Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AmpliPhi Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AmpliPhi Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AmpliPhi Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AmpliPhi Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AmpliPhi Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Grint
COMPENSATION $618,000
AGE 60
TENURE AS CEO 1.9 years
CEO Bio

Dr. Paul C. Grint, M.D., has been the Chief Executive Officer of AmpliPhi Biosciences Corporation since May 31, 2017. Dr. Grint served as the Chief Executive Officer and President of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017 and served as its Chief Medical Officer from June 16, 2014 to June 1, 2015. Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to Regulus, Dr. Grint served as the President at Cerexa, Inc. and was responsible for the oversight of Anti-Infective product development. Prior to joining Cerexa, he served as Senior Vice President at Forest Research Institute, Inc. He served as the Chief Medical Officer and Head of Development at Kalypsys, Inc. He served as Chief Medical Officer and Senior Vice President of Zephyr Sciences, Inc. Prior to joining Zephyr, Dr. Grint served as Vice President and Head of Clinical Research and Development of Pfizer Inc. in La Jolla. He served in executive level positions at Pfizer Inc., IDEC Pharmaceuticals Corporation and Schering-Plough Corporation. He served as Chief Medical Officer and Senior Vice President of Medical and Clinical Research and Development at Biogen Inc. since January 2001. Prior to joining Biogen, Dr. Grint was employed with Schering-Plough Research Institute from 1992 to 2000 and served as its Vice President of Clinical Immunology and Biotechnology. He has been a Director at AmpliPhi Biosciences Corporation since November 2015. He has been a Director of Amplyx Pharmaceuticals, Inc. since May 24, 2016. He serves as a Member of Advisory Board at CovX Research LLC. He served as a Director at Numira Biosciences, Inc. He served as a Director of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017. He served as Member of Scientific Advisory Board at MultiCell Technologies, Inc. He served as a Member of clinical Advisory Board of Tobira Therapeutics, Inc. Dr. Grint served as a Director of Illumina Inc. from April 12, 2005 to May 29, 2013. He serves as Chairman of the Advisory Council of the Keck Graduate Institute. He served as the Chairman of the Biotechnology Therapy Team at St. Bartholomew's Hospital in London. He served as an Honorary Lecturer in the Department of Virology at St. Bartholomew's Hospital in London. Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies and the author or co-author of over fifty scientific publications. Dr. Grint received his Medical Degree from the University of London, St. Bartholomew's Hospital Medical College in London, U.K. He has a B.S. in Medical Science from Barts & The London School of Medicine & Dentistry, Queen Mary University of London.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year.
  • Paul's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AmpliPhi Biosciences management team in years:

1.9
Average Tenure
57
Average Age
  • The average tenure for the AmpliPhi Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Paul Grint

TITLE
CEO & Director
COMPENSATION
$618K
AGE
60
TENURE
1.9 yrs

Steve Martin

TITLE
Senior VP & CFO
COMPENSATION
$429K
AGE
57
TENURE
3.3 yrs

Michael Salka

TITLE
Consultant
COMPENSATION
$1M
AGE
56
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the AmpliPhi Biosciences board of directors in years:

4.9
Average Tenure
65.5
Average Age
  • The tenure for the AmpliPhi Biosciences board of directors is about average.
Board of Directors

Jeremy Curnock Cook

TITLE
Chairman of the Board
COMPENSATION
$70K
AGE
68
TENURE
21.2 yrs

Paul Grint

TITLE
CEO & Director
COMPENSATION
$618K
AGE
60
TENURE
3.4 yrs

Mike Perry

TITLE
Independent Director
COMPENSATION
$59K
AGE
59
TENURE
13.4 yrs

Louis Drapeau

TITLE
Independent Director
COMPENSATION
$63K
AGE
74
TENURE
8.1 yrs

Tim Lu

TITLE
Chairman of Scientific Advisory Board
TENURE
2.2 yrs

Wendy Johnson

TITLE
Director
COMPENSATION
$40K
AGE
66
TENURE
4.9 yrs

Vijay Samant

TITLE
Non-Executive Director
COMPENSATION
$46K
AGE
65
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess AmpliPhi Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AmpliPhi Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Details
Name: AmpliPhi Biosciences Corporation
TG1M
Exchange: DB
Founded: 1989
$8,970,402
32,774,690
Website: http://www.ampliphibio.com
Address: AmpliPhi Biosciences Corporation
3579 Valley Centre Drive,
Suite 100,
San Diego,
California, 92130,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX APHB Common Stock NYSE MKT LLC US USD 20. May 1994
DB TG1M Common Stock Deutsche Boerse AG DE EUR 20. May 1994
Number of employees
Current staff
Staff numbers
30
AmpliPhi Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:57
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2019/03/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.